ANTIBACTERIAL ACTIVITY AND CLINICAL TRIAL OF AC-1370 IN THE FIELD OF OBSTETRICS AND GYNECOLOGY
スポンサーリンク
概要
- 論文の詳細を見る
Antibacterial activity of AC-1370 was determined by agar plate methods against clinical isolates from obstetrical and gynecological infections including urinary tract infections. Against about 80 percents of <I>E. coli</I> used this chemotherapeutic agent showed less than 50μg/ml in MIC. This drug required 50μg/ml to inhibit 80% of 107 strains of genus <I>Staphylococcus</I>.<BR>It also required 50μg/ml to inhibit 80% of 106 strains of anaerobic Gram positive cocci and <I>Bacteroides</I> of 62 strains (63.9%) was susceptible to this concentration of this drug.<BR>Nine out of ten patients with obsterical or gynecological infections (one case of adnexitis, Bartholine's abscess intrauterine infection and cystitis and 6 cases of acute mastitis) responded well to the administration of AC-1370. This new chemotherapeutic agent did not cause any noteworthy adverse reactions or laboratory data abnormalities throughout this clinical trials.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.